Correlation of DNA-PK activity with anti-cancer drug-sensitivity in human gliomas.
- Author:
Cui-jie SHAO
1
;
Yun-fei XIA
;
Hong-liu SHI
;
Jun-Ying ZHANG
;
Yu-Xiang HE
;
Zhong-ping CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Antineoplastic Agents, Phytogenic; pharmacology; Cisplatin; pharmacology; DNA-Activated Protein Kinase; metabolism; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glioma; enzymology; pathology; Humans; Nuclear Proteins; metabolism; Vincristine; pharmacology
- From: Chinese Journal of Oncology 2006;28(5):342-344
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the relationship between DNA-dependent protein kinase (DNA-PK) activity and anti-cancer drug sensitivity in human glioma tissues.
METHODSHuman glioma specimens were primarily cultured and its sensitivity to several anti-cancer drugs were evaluated by MTT assay. Nuclear protein was extracted from the glioma sample of the same patient and its DNA-PK activity was determined by a biotinylated DNA-PK assay with p53-derived peptide as a specific substrate.
RESULTSDNA-PK activity varied widely among these glioma samples. Of all 36 samples, 16 showed higher DNA-PK activity (relative activity > or = 0.40) and 20 samples with lower DNA-PK activity (relative activity < 0.40). The gliomas sensitive to DDP and VCR as evaluated by inhibition rate (IR > or = 50%) under plasma peak concentration (PPC) showed lower DNA-PK activity than the resistant ones (IR < 50%) (t = -3.445, P < 0.01). Furthermore, the gliomas with higher DNA-PK activity showed lower inhibition rate (IR < 50%) than those with lower DNA-PK activity ones (t = -2.145, P < 0.05).
CONCLUSIONDNA-PK activity is significantly associated with anti-cancer drug sensitivity to DDP and VCR in human gliomas. DNA-PK activity could be used as a new biomarker for the chemotherapy sensitivity of human gliomas.
